Genmab — Marts 2011
-
alt fik hammeren idag
-
Ja,men det betød en supplering i portføljen,så må man se......
-
Nyt studie med ofatumumab http://clinicaltrials.gov/ct2/show/NCT01313689?term=ofatumumab&rank=26
-
Der er tale om et studie som er en del af den betingede godkendelse i EU
-
har lige opdateret genmab side med arzerra salgstal datoer. http://www.proinvestor.com/aktier/Genmab/GEN.CO
-
fedt at høre drenge
-
og Gentogen endnu federe!
-
min respekt for Jan vokser hver dag
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind